Does Chemotherapy — Actually Work?

Your team will check at planned intervals using scans, blood markers, or both — depending on your cancer type. The timing varies: some cancers are reassessed after two or three cycles, others after the full course. Your symptoms also matter — relief from pain, return of appetite, or reduced swelling can be early signals, though your team will interpret these alongside objective results. Ask your oncologist when the first assessment is planned and what they will be looking for, so you are not waiting without a timeline.

No. Side effects are caused by chemotherapy affecting fast-dividing healthy cells alongside cancer cells. The intensity of those effects does not predict how well the cancer is responding. Some people have significant side effects from a regimen that is not working, and others tolerate treatment well while achieving a good response. If your side effects are severe, tell your team — they can often be managed, and enduring them in silence is not a sign of better treatment.

Remission means no cancer is detectable on current scans or markers. It is not the same as cure, because cells below the level of detection may still be present in some situations. Whether remission in your case carries a high or low risk of return depends on the cancer type, the stage at diagnosis, and the tumour's biology. Your oncologist can tell you what remission means for your specific cancer — the word alone, without that context, does not tell you enough.

Tell your oncology team everything you are taking, including herbal preparations, Ayurvedic medicines, supplements and over-the-counter products. Some interact with chemotherapy drugs by affecting how the liver processes them — either reducing the drug's effect or increasing its toxicity. Your team is not asking you to abandon traditional practices. They need the information so they can flag anything that could affect your treatment. Telling them is protecting the effectiveness of the chemotherapy, not a conflict with your other choices.

Resistance means the cancer has found a way to survive the drug that was targeting it. It is a property of the tumour cells, not a failure on your part. When resistance develops, your team will look at what alternatives are available — a different drug class, targeted therapy if a new mutation is identified on re-biopsy, or immunotherapy if your tumour qualifies. The options depend on your cancer type and what has already been tried. Resistance narrows the path but rarely closes it entirely.

Because the same cancer type can be many different diseases at the molecular level. Two people with the same diagnosis can have tumours with different gene mutations, different protein expression and different immune environments — all of which affect how the cancer responds to the same drug. This is why biomarker and molecular testing exists, and why treatment is increasingly guided by the tumour's biology rather than its location alone. Someone else's experience, which almost never comes with that molecular detail, is a poor guide to what will happen for you.